GeneDx Holdings WGS Diagnostic Test — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about GeneDx Holdings's diagnostic test — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GeneDx Holdings's diagnostic test — total revenue?
- GeneDx Holdings (WGS) reported diagnostic test — total revenue of $101.3M in Q1 2026.
- How has GeneDx Holdings's diagnostic test — total revenue changed year-over-year?
- GeneDx Holdings's diagnostic test — total revenue increased by 18.1% year-over-year, from $85.76M to $101.3M.
- What is the long-term trend for GeneDx Holdings's diagnostic test — total revenue?
- Over 4 years (2021 to 2025), GeneDx Holdings's diagnostic test — total revenue has grown at a 19.4% compound annual growth rate (CAGR), from $205.1M to $416.39M.
- What does diagnostic test — total revenue mean?
- This metric represents the total gross revenue generated from the sale and delivery of diagnostic testing services within a specific business segment. It reflects the market demand and commercial adoption of the company's diagnostic portfolio. Monitoring this figure helps investors assess the top-line growth trajectory and competitive positioning of the segment's core offerings.